Forbes August 7, 2024
This year will be regarded as an inflection point for the treatment of glioblastoma, a rare and aggressive form of brain cancer that carries a median survival time of around 15 to 18 months, said Carl June, professor at the University of Pennsylvania Perelman School of Medicine and renowned immunologist.
“It’s basically a death sentence,” explains June, who led a team that pioneered the first CAR T-cell therapy to treat certain blood cancers. Pediatricians “basically say, ‘Go home, there’s nothing we can do,’” But recent studies, including one led by June, have shown promise in CAR T-Cell infusions for glioblastoma treatment.
Few people on the planet have changed the world for the better as profoundly as Carl June. I spoke...
Today's Sponsors
Today's Sponsor